TABLE 2.
Pharmacokinetic data from subjects (n = 6) who exhibited a linear plasma folate response after caplet ingestion of 855 nmol [13C5]5-formyltetrahydrofolate1
| Caplet disintegration | ||||||||
| Plasma volume | Sex | t delay | C max | t max | Rate of appearance | Initiation location | Completion location | |
| L | h | nmol | h | nmol/h | ||||
| Subject | ||||||||
| A | 2.21 | F | 5 | 3.7 | 6.0 | 0.72 | ICJ | Cecum |
| B | 4.07 | M | 8 | 4.0 | 10.0 | 0.37 | Cecum | Ascending |
| C | 1.87 | F | 4 | 1.6 | 5.5 | 0.31 | ICJ | Ascending |
| D | 3.54 | M | 6 | 3.7 | 7.1 | 0.33 | Cecum | Ascending |
| E | 2.77 | M | 6 | 0.5 | 10.1 | 0.05 | Cecum | ND2 |
| F | 2.38 | F | 7 | 2.0 | 10.0 | 0.21 | ICJ | Ascending |
| Mean ± SEM | 2.9 ± 0.3 | — | 6.6 ± 1.0 | 2.6 ± 0.6 | 8.7 ± 0.9 | 0.33 ± 0.09 | — | — |
1
Rate of appearance was determined from the ascending slope for the concentration of labeled [13C5]5-methyltetrahydrofolate in the plasma of 6 subjects with complete caplet disintegration. Cmax, maximal concentration; ICJ, ileocecal junction; ND, not detected; tdelay, time lag before detection of [13C5]5-methyltetrahyrofolate in plasma after caplet ingestion (baseline) in 6 subjects; tmax, time of maximal concentration.
2
Last image was taken in the transverse colon.